Skip to content
The Policy VaultThe Policy Vault

Tarceva (erlotinib) — Highmark

metastatic NSCLC

Initial criteria

  • age ≥ 18 years
  • Diagnosis of metastatic NSCLC (ICD‑10: C34) AND disease harbors EGFR exon 19 deletions OR EGFR exon 21 (L858R) substitution mutations